Pfizer-BioNTech has applied to the Food and Drug Administration for the emergency authorization of a fourth dose of its anti-covid vaccine for US citizens over the age of 65. This would be the second booster to be given to the elderly.
For the full approval of the fourth dose, it will take, in addition to the approval of the FDA, also that of the Centers for Disease Control and Prevention. Health authorities currently recommend two primary doses for the entire population 12 years and older, followed by a booster dose.
Modern versus Pfizer-BioNtech, that’s why pharmaceutical companies are competing for new anti Covid vaccines
by Anja Ettel
A note from Pfizer explains that the request for the fourth dose for those over 65 is based on two sets of data that come from Israel. Both datasets – reports the company – have shown that an additional booster of the vaccine increases immunity and decreases infections and the onset of serious disease.